To establish a process by which critically ill infants with parenteral nutrition-associated liver disease can receive a fish oil-based intravenous lipid emulsion (Omegaven®) for compassionate use when no satisfactory alternative treatments are available.
Patients who meet the inclusion criteria (having a direct bilirubin ≥4.0 mg/dL) and are consented will be discontinued from standard soybean-based lipid emulsion and started on Omegaven®. Omegaven® will be infused continuously via either a peripheral or central catheter at a dose of 1 gm/kg/day along with parenteral nutrition (PN).
Study Type
EXPANDED_ACCESS
IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
University Health System
San Antonio, Texas, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.